| Literature DB >> 28673046 |
Ilene K Gipson1, Ulla Mandel2, Balaraj Menon1, Sandra Michaud1, Ann Tisdale1, Diana Campos3,4, Henrik Clausen2.
Abstract
MUC16 is a large transmembrane mucin expressed on the apical surfaces of the epithelium covering the ocular surface, respiratory system and female reproductive tract. The transmembrane mucin is overexpressed by ovarian carcinomas, it is one of the most frequently used diagnostic markers for the disease and it is considered a promising target for immunotherapeutic intervention. Immunodetection of the mucin has to date been through antibodies that recognize its exceptionally large ectodomain. Similar to other membrane anchored mucins, MUC16 has a short cytoplasmic tail (CT), but studies of the biological relevance of the C-terminal domain of MUC16 has been limited by lack of availability of monoclonal antibodies that recognize the native CT. Here, we report the development of a novel monoclonal antibody to the CT region of the molecule that recognizes native MUC16 and its enzymatically released CT region. The antibody is useful for immunoprecipitation of the released CT domain as demonstrated with the OVCAR3 ovarian cancer cell line and can be used for detailed cytolocalization in cells as well as in frozen sections of ocular surface and uterine epithelium.Entities:
Keywords: CA125; MUC16 MAb; MUC16 cytoplasmic tail; transmembrane mucin
Mesh:
Substances:
Year: 2017 PMID: 28673046 PMCID: PMC6283312 DOI: 10.1093/glycob/cwx054
Source DB: PubMed Journal: Glycobiology ISSN: 0959-6658 Impact factor: 4.313